

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Zaghouni et al.) DOCKET:	07316.0002.CPUS01
)	
SERIAL NO.:	10/681,788) GROUP ART UNIT:	1644
)	
FILED:	October 8, 2003) EXAMINER:	Ewoldt, G.R.
)	
TITLE:	Sustained treatment of type-1 diabetes after expression of predisposition markers		
DATE:	June 19, 2007	CUSTOMER NO.	22930

AMENDMENT TO SEQUENCE LISTING UNDER 37 C.F.R. § 1.825

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

In response to the Official Communication dated January 19, 2007, Applicants amend the Sequence Listing in the above-reference application pursuant to 37 C.F.R. § 1.825. Submitted herewith is a substitute copy of the computer readable form of the Sequence Listing in accordance with 37 C.F.R. § 1.825(b).

The Sequence Listing, as originally filed, has been amended to conform to sequences and associated information using the symbols and format in accordance with the requirements of §§1.822 and 1.823. Accordingly, I hereby state that the electronic copy of the Sequence Listing does not include new matter, nor does it extend beyond the original disclosure.

Respectfully submitted,

HOWREY LLP

By:



 David B. Fournier
 Registration No. 51,696
 Telephone: (312) 846-5621
 Facsimile: (312) 264-0365

CUSTOMER NUMBER 22930
 C/O IP DOCKETING DEPARTMENT
 HOWREY, LLP
 2941 FAIRVIEW PARK DR. STE 200
 FALLS CHURCH, VA 22042-9922
 Telephone No.: (703) 663-3600
 Facsimile No.: (202) 383-7195